• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series.

作者信息

Anzengruber F, Drach M, Maul J-T, Kolios A G, Meier B, Navarini A A

机构信息

Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091, Zurich, Switzerland.

Faculty of Medicine, University of Zurich, Pestalozzistrasse 3, 8091, Zurich, Switzerland.

出版信息

J Eur Acad Dermatol Venereol. 2018 Jul;32(7):e274-e276. doi: 10.1111/jdv.14808. Epub 2018 Feb 27.

DOI:10.1111/jdv.14808
PMID:29356172
Abstract
摘要

相似文献

1
Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series.在用司库奇尤单抗治疗的银屑病患者中，治疗反应不受HLA - Cw6状态的影响：一项回顾性病例系列研究。
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):e274-e276. doi: 10.1111/jdv.14808. Epub 2018 Feb 27.
2
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.司库奇尤单抗治疗中重度斑块状银屑病的疗效与 HLA-Cw6 状态无关：SUPREME 研究。
Br J Dermatol. 2018 Nov;179(5):1072-1080. doi: 10.1111/bjd.16705. Epub 2018 Aug 14.
3
Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.人类白细胞抗原-Cw6 作为预测乌司奴单抗（一种白介素-12/23 阻滞剂）在中国银屑病患者临床应答的标志物：一项回顾性分析。
Br J Dermatol. 2014 Nov;171(5):1181-8. doi: 10.1111/bjd.13056. Epub 2014 Oct 15.
4
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.IL12B（p40）基因多态性有助于银屑病中乌司奴单抗疗效的预测。
Dermatology. 2016;232(2):230-6. doi: 10.1159/000441719. Epub 2015 Dec 18.
5
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.HLA-C*06与白种人银屑病患者对乌司奴单抗的反应：结果与长期随访
J Am Acad Dermatol. 2016 Feb;74(2):374-5. doi: 10.1016/j.jaad.2015.08.055.
6
Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.银屑病药物遗传学：HLA - Cw*0602作为乌司奴单抗治疗反应的标志物
Eur J Dermatol. 2017 Oct 1;27(5):528-530. doi: 10.1684/ejd.2017.3071.
7
HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis.中国人慢性斑块状银屑病患者的 HLA 多态性：亚组分析。
Br J Dermatol. 2012 Feb;166(2):288-97. doi: 10.1111/j.1365-2133.2011.10688.x. Epub 2012 Jan 9.
8
HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment.银屑病 HLA-Cw6 阳性患者对甲氨蝶呤治疗的反应改善。
Clin Exp Dermatol. 2017 Aug;42(6):651-655. doi: 10.1111/ced.13100. Epub 2017 May 17.
9
and other HLA-C alleles, as well as and genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis.以及其他 HLA-C 等位基因，以及 和 遗传变异与银屑病患者对抗 IL-17A 治疗的最佳反应相关。
Expert Opin Biol Ther. 2021 Feb;21(2):259-270. doi: 10.1080/14712598.2021.1862082. Epub 2020 Dec 28.
10
Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.HLA-C*06 等位基因在乌司奴单抗临床应答中的作用：来自大型欧洲患者队列的真实生活证据。
Br J Dermatol. 2017 Aug;177(2):489-496. doi: 10.1111/bjd.15387. Epub 2017 Jun 22.

引用本文的文献

1
Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.遗传因素对银屑病治疗反应的影响：个性化医学的新见解。
Int J Mol Sci. 2023 Jun 7;24(12):9850. doi: 10.3390/ijms24129850.
2
Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review.药物基因组学在银屑病患者治疗反应中的作用：更新综述。
Int J Mol Sci. 2023 Apr 15;24(8):7329. doi: 10.3390/ijms24087329.
3
Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.药物组学在银屑病中的应用：迈向个体化医学之路。
Int J Mol Sci. 2023 Apr 11;24(8):7090. doi: 10.3390/ijms24087090.
4
Towards Personalized Medicine in Psoriasis: Current Progress.银屑病的个性化医疗：当前进展
Psoriasis (Auckl). 2022 Sep 1;12:231-250. doi: 10.2147/PTT.S328460. eCollection 2022.
5
Comparison of Efficacy of Anti-interleukin-17 in the Treatment of Psoriasis Between Caucasians and Asians: A Systematic Review and Meta-Analysis.白种人与亚洲人抗白细胞介素-17治疗银屑病疗效的比较：一项系统评价和荟萃分析
Front Med (Lausanne). 2022 Jan 25;8:814938. doi: 10.3389/fmed.2021.814938. eCollection 2021.
6
Pharmacogenetics Update on Biologic Therapy in Psoriasis.银屑病生物治疗的药物遗传学最新进展。
Medicina (Kaunas). 2020 Dec 20;56(12):719. doi: 10.3390/medicina56120719.
7
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.针对白细胞介素 17A（IL-17A）抑制剂司库奇尤单抗和依奇珠单抗的反应不能用 IL-17A 基因的蛋白编码区和非翻译区的遗传变异来解释：来自四个欧洲银屑病队列的多中心研究结果。
J Eur Acad Dermatol Venereol. 2020 Jan;34(1):112-118. doi: 10.1111/jdv.15787. Epub 2019 Aug 5.